Los Angeles Capital Management
LXEO icon

Los Angeles Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Los Angeles Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
48,176
+11,105
+30% +$60.1K ﹤0.01% 1139
2026
Q1 		$213K Buy
37,071
+25,516
+221% +$181K ﹤0.01% 1126
2025
Q4 		$109K Buy
11,555
+480
+4% +$4.38K ﹤0.01% 1396
2025
Q3 		$73.5K Buy
+11,075
New +$53.6K ﹤0.01% 1327

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Los Angeles Capital Management's LXEO Position: Q2 2026 in Review

Los Angeles Capital Management increased its Lexeo Therapeutics (LXEO) stake by 30% in Q2 2026, buying an estimated $60.1K and bringing the position to 48,176 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Los Angeles Capital Management first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Los Angeles Capital Management held 48,176 shares of Lexeo Therapeutics worth $224K as of Q2 2026.
  • Los Angeles Capital Management bought 11,105 Lexeo Therapeutics shares in Q2 2026, an estimated $60.1K.
  • Lexeo Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1139 holding.
  • Los Angeles Capital Management first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.